Prevalence of Serum Markers of HGV, HCV, and HIV in Blood Donors and Hemophiliacs Treated With Different Types of Concentrates
| Virus . | Blood Donors* . | Recipients of Concentrates . | |||
|---|---|---|---|---|---|
| . | (N = 200) . | Unmodified† . | Inactivated‡ . | Recombinant . | All . |
| . | . | (n = 128) . | (n = 33) . | (n = 7) . | (n = 168) . |
| HGV | |||||
| RNA | 3 (1.5%) | 11 (9%) | 1 (3%) | 0 | 12 (7%) |
| Antibody | 10 (5%) | 41 (32%) | 5 (15%) | 0 | 46 (27%) |
| Either | 13 (6.5%) | 50 (39%) | 6 (18%) | 0 | 56 (33%) |
| HCV | |||||
| RNA | 0 | 107 (86%) | 5 (15%) | 0 | 112 (67%) |
| Antibody | 0 | 125 (98%) | 6 (18%) | 0 | 131 (78%) |
| Either | 0 | 125 (98%) | 6 (18%) | 0 | 131 (78%) |
| HBsAg | 0 | 7 (5%) | 0 | 0 | 7 (4%) |
| Anti-HIV | 0 | 30 (23%) | 0 | 0 | 30 (18%) |
| Virus . | Blood Donors* . | Recipients of Concentrates . | |||
|---|---|---|---|---|---|
| . | (N = 200) . | Unmodified† . | Inactivated‡ . | Recombinant . | All . |
| . | . | (n = 128) . | (n = 33) . | (n = 7) . | (n = 168) . |
| HGV | |||||
| RNA | 3 (1.5%) | 11 (9%) | 1 (3%) | 0 | 12 (7%) |
| Antibody | 10 (5%) | 41 (32%) | 5 (15%) | 0 | 46 (27%) |
| Either | 13 (6.5%) | 50 (39%) | 6 (18%) | 0 | 56 (33%) |
| HCV | |||||
| RNA | 0 | 107 (86%) | 5 (15%) | 0 | 112 (67%) |
| Antibody | 0 | 125 (98%) | 6 (18%) | 0 | 131 (78%) |
| Either | 0 | 125 (98%) | 6 (18%) | 0 | 131 (78%) |
| HBsAg | 0 | 7 (5%) | 0 | 0 | 7 (4%) |
| Anti-HIV | 0 | 30 (23%) | 0 | 0 | 30 (18%) |
versus †: HGV-RNA P = .002, HCV RNA P < .0001, anti-HGV P < .0001, anti-HCV P < .0001, anti-HIV P < .0001.
versus ‡: HGV-RNA P = not significant, HCV RNA P < .0001, anti-HGV P = not significant, anti-HCV P < .0001, anti-HIV P < .001.